First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer.

Sung-Bae KimFunda Meric-BernstamAparna KalyanAleksei BabichRong LiuTakahiko TanigawaAnette SommerMotonobu OsadaFrank ReetzDirk LaurentSabine Wittemer-RumpJordan Berlin

Published in: Targeted oncology (2020)

NCT02368951.

Keyphrases

advanced cancer
palliative care
endothelial cells
induced pluripotent stem cells
cancer therapy